Gofen & Glossberg LLC IL Purchases New Position in GW Pharmaceuticals PLC- (GWPH)

Share on StockTwits

Gofen & Glossberg LLC IL purchased a new stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 2,060 shares of the biopharmaceutical company’s stock, valued at approximately $356,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. WealthTrust Fairport LLC bought a new position in shares of GW Pharmaceuticals PLC- in the 1st quarter valued at $104,000. Flagship Harbor Advisors LLC bought a new position in GW Pharmaceuticals PLC- during the 2nd quarter worth $109,000. Envestnet Asset Management Inc. bought a new position in GW Pharmaceuticals PLC- during the 2nd quarter worth $119,000. Cowen Prime Services LLC raised its position in GW Pharmaceuticals PLC- by 708.0% during the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 885 shares during the last quarter. Finally, NumerixS Investment Technologies Inc bought a new position in GW Pharmaceuticals PLC- during the 2nd quarter worth $166,000. Institutional investors own 75.44% of the company’s stock.

Shares of NASDAQ:GWPH opened at $143.32 on Friday. The firm has a market cap of $4.80 billion, a P/E ratio of -20.62 and a beta of 2.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.67 and a quick ratio of 8.21. GW Pharmaceuticals PLC- has a 12-month low of $101.07 and a 12-month high of $179.65.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.40) by $1.14. GW Pharmaceuticals PLC- had a negative return on equity of 47.65% and a negative net margin of 1,392.61%. The firm had revenue of $3.46 million during the quarter, compared to analyst estimates of $2.00 million. Analysts expect that GW Pharmaceuticals PLC- will post -9.11 earnings per share for the current fiscal year.

GWPH has been the subject of several analyst reports. Bank of America raised their target price on GW Pharmaceuticals PLC- from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, June 26th. Cantor Fitzgerald set a $211.00 target price on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Thursday, September 27th. BidaskClub raised GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Stifel Nicolaus initiated coverage on GW Pharmaceuticals PLC- in a research report on Tuesday, August 14th. They set a “buy” rating and a $181.00 target price for the company. Finally, Morgan Stanley set a $227.00 target price on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Thursday. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC- presently has a consensus rating of “Buy” and an average price target of $185.00.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Story: Penny Stocks, What You Need To Know

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply